Tcr2 Therapeutics (NASDAQ:TCRR) Raised to Buy at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Tcr2 Therapeutics (NASDAQ:TCRR) from a hold rating to a buy rating in a research report report published on Thursday, Zacks.com reports. They currently have $17.00 price target on the stock.

According to Zacks, “TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer. Its product candidate includes TC-210, TC-220, TC-410, TC-110 and TC-310 which are in clinical stage. TCR2 Therapeutics Inc. is based in Cambridge, Massachusetts. “

A number of other research firms also recently issued reports on TCRR. Roth Capital started coverage on shares of Tcr2 Therapeutics in a research report on Friday, May 31st. They set a neutral rating and a $16.00 target price for the company. ValuEngine upgraded shares of Tcr2 Therapeutics from a hold rating to a buy rating in a research report on Thursday, August 8th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Tcr2 Therapeutics has an average rating of Buy and a consensus target price of $26.00.

NASDAQ TCRR opened at $15.94 on Thursday. The firm has a market capitalization of $363.55 million and a P/E ratio of -0.16. The firm’s fifty day simple moving average is $14.13. Tcr2 Therapeutics has a 1 year low of $10.04 and a 1 year high of $25.47.

Tcr2 Therapeutics (NASDAQ:TCRR) last posted its earnings results on Thursday, August 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.11. As a group, analysts expect that Tcr2 Therapeutics will post -5.66 EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of TCRR. EcoR1 Capital LLC acquired a new position in shares of Tcr2 Therapeutics in the second quarter worth about $231,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Tcr2 Therapeutics in the second quarter worth about $349,000. Laurion Capital Management LP acquired a new position in shares of Tcr2 Therapeutics in the first quarter worth about $417,000. Parametric Portfolio Associates LLC raised its position in shares of Tcr2 Therapeutics by 23.5% in the second quarter. Parametric Portfolio Associates LLC now owns 35,044 shares of the company’s stock worth $501,000 after acquiring an additional 6,672 shares during the period. Finally, Dean Capital Investments Management LLC acquired a new position in shares of Tcr2 Therapeutics in the first quarter worth about $694,000. Institutional investors own 33.26% of the company’s stock.

About Tcr2 Therapeutics

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

Featured Story: Quick Ratio

Get a free copy of the Zacks research report on Tcr2 Therapeutics (TCRR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Tcr2 Therapeutics (NASDAQ:TCRR)

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Swiss National Bank Buys 4,900 Shares of ChannelAdvisor Corp
Swiss National Bank Buys 4,900 Shares of ChannelAdvisor Corp
Doheny Asset Management CA Buys 960 Shares of AT&T Inc.
Doheny Asset Management CA Buys 960 Shares of AT&T Inc.
Doheny Asset Management CA Buys 2,865 Shares of Xilinx, Inc.
Doheny Asset Management CA Buys 2,865 Shares of Xilinx, Inc.
$1.31 EPS Expected for Microchip Technology Inc.  This Quarter
$1.31 EPS Expected for Microchip Technology Inc. This Quarter
Doheny Asset Management CA Has $387,000 Stock Holdings in Lowe’s Companies, Inc.
Doheny Asset Management CA Has $387,000 Stock Holdings in Lowe’s Companies, Inc.
-$0.63 Earnings Per Share Expected for Instructure Inc  This Quarter
-$0.63 Earnings Per Share Expected for Instructure Inc This Quarter


© 2006-2019 Ticker Report